FAS Gene Mutation in a Case of Autoimmune Lymphoproliferative Syndrome Type IA With Accumulation of γδ+ T CellsAnke van den Berg, Sibrand Poppema, R. Y. J. Tamminga et al.|The American Journal of Surgical Pathology|2003Cited by 11
P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, Fenna M. Jansen et al.|Journal of Crohn s and Colitis|2023Cited by 0
P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trialMartine Devillers, Frank Hoentjen, Robbart van Linschoten et al.|Journal of Crohn s and Colitis|2025Cited by 0